Clearside Biomedical (CLSD) News Today $0.87 -0.06 (-6.20%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Clearside announces publication of insights on drug development, regulationDecember 20 at 9:03 PM | finance.yahoo.comAnalysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.33December 20 at 1:24 AM | americanbankingnews.comClearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, EyeDecember 19 at 7:05 AM | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Receives Consensus Rating of "Buy" from BrokeragesShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year targDecember 17, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 11.8% in NovemberClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 1,340,000 shares, a decline of 11.8% from the November 15th total of 1,520,000 shares. Based on an average daily trading volume, of 726,200 shares, the days-to-cover ratio is currently 1.8 days.December 16, 2024 | marketbeat.comClearside Biomedical Highlights Advancements in Drug DeliveryDecember 14, 2024 | markets.businessinsider.comClearside Biomedical (NASDAQ:CLSD) Rating Increased to Hold at StockNews.comStockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Thursday.December 12, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest UpdateClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 1,520,000 shares, a decrease of 13.6% from the October 31st total of 1,760,000 shares. Based on an average daily trading volume, of 750,800 shares, the days-to-cover ratio is presently 2.0 days.December 1, 2024 | marketbeat.comClearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United StatesNovember 25, 2024 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by AnalystsShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have earned a consensus recommendation of "Buy" from the six brokerages that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among brokersNovember 22, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CLSD FY2024 Earnings?Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings estimates for Clearside Biomedical in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst Y. Chen now anticipates that the cNovember 18, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short InterestClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,760,000 shares, a decrease of 9.7% from the October 15th total of 1,950,000 shares. Based on an average daily trading volume, of 735,800 shares, the short-interest ratio is presently 2.4 days.November 17, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.comStockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a research note on Saturday.November 16, 2024 | marketbeat.comClearside Biomedical's (CLSD) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Friday.November 15, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Thursday.November 14, 2024 | marketbeat.comPromising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash PositionNovember 13, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Clearside Biomedical (CLSD)November 13, 2024 | markets.businessinsider.comNeedham & Company LLC Reaffirms "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)Needham & Company LLC restated a "buy" rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Wednesday.November 13, 2024 | marketbeat.comClearside Biomedical Reports Positive Q3 2024 ResultsNovember 13, 2024 | markets.businessinsider.comClearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...November 13, 2024 | finance.yahoo.comClearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | markets.businessinsider.comClearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call TranscriptNovember 12, 2024 | seekingalpha.comClearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look ForNovember 11, 2024 | finance.yahoo.comEven after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three yearsNovember 10, 2024 | finance.yahoo.comClearside Biomedical (NASDAQ:CLSD) Rating Lowered to "Sell" at StockNews.comStockNews.com cut shares of Clearside Biomedical from a "hold" rating to a "sell" rating in a research report on Friday.November 8, 2024 | marketbeat.comClearside Biomedical’s partner signed new collaboration agreement with SantenNovember 7, 2024 | markets.businessinsider.comClearside Biomedical, Inc. (NASDAQ:CLSD) Shares Sold by Rosalind Advisors Inc.Rosalind Advisors Inc. lessened its holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) by 95.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 127,220 shares of the company's stock after selling 2,465,3November 6, 2024 | marketbeat.comClearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceNovember 6, 2024 | globenewswire.comClearside Biomedical (CLSD) to Release Earnings on TuesdayClearside Biomedical (NASDAQ:CLSD) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=263163)November 5, 2024 | marketbeat.comClearside Biomedical appoints Gibney as new Chair of board of directorsNovember 5, 2024 | markets.businessinsider.comClearside Biomedical, Inc. (NASDAQ:CLSD) Insider Ngai Hang Victor Chong Purchases 36,500 SharesNovember 5, 2024 | insidertrades.comClearside Biomedical, Inc. (NASDAQ:CLSD) Insider Purchases $36,500.00 in StockClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) insider Ngai Hang Victor Chong acquired 36,500 shares of the business's stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $1.00 per share, for a total transaction of $36,500.00. Following the completion of the acquisition, the insider now directly owns 100,000 shares of the company's stock, valued at approximately $100,000. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link.November 4, 2024 | marketbeat.comClearside Biomedical Appoints Tony Gibney as New Chair of the Board of DirectorsNovember 4, 2024 | globenewswire.comClearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024October 31, 2024 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Growth in Short InterestClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,950,000 shares, an increase of 646.6% from the September 30th total of 261,200 shares. Based on an average daily volume of 718,700 shares, the days-to-cover ratio is presently 2.7 days.October 25, 2024 | marketbeat.comClearside Biomedical announces multiple presentations delivered at 2024 AAOOctober 22, 2024 | markets.businessinsider.comClearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual MeetingOctober 22, 2024 | globenewswire.comChardan Capital Reaffirms "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)Chardan Capital reaffirmed a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a report on Monday.October 14, 2024 | marketbeat.comMorning Movers: Arcadium Lithium surges after deal to be acquiredOctober 11, 2024 | finance.yahoo.comClearside Biomedical’s CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating with a $6.00 TargetOctober 10, 2024 | markets.businessinsider.comBuy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial SuccessOctober 10, 2024 | markets.businessinsider.comBuy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market PositionOctober 9, 2024 | markets.businessinsider.comClearside stock falls 12% amid Phase 2 data for CLS-AXOctober 9, 2024 | msn.comClearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage StudyOctober 9, 2024 | finance.yahoo.comClearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary OutcomesOctober 9, 2024 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Buy" by AnalystsClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) has been given a consensus recommendation of "Buy" by the six brokerages that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1 year target price among brokers that haveOctober 3, 2024 | marketbeat.comArmistice Capital LLC Decreases Position in Clearside Biomedical, Inc. (NASDAQ:CLSD)Armistice Capital LLC lessened its stake in Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) by 46.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,136,000 shares of the company's stock after selling 1,820,000 sharSeptember 27, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Sees Large Increase in Short InterestClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 335,200 shares, an increase of 86.0% from the August 15th total of 180,200 shares. Based on an average daily trading volume, of 220,800 shares, the days-to-cover ratio is currently 1.5 days.September 13, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Rating of "Buy" from BrokeragesClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) has been assigned a consensus rating of "Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among brokeragSeptember 8, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving Average of $1.12Clearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving Average of $1.12September 6, 2024 | marketbeat.com Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] CLSD Media Mentions By Week CLSD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLSD News Sentiment▼0.540.60▲Average Medical News Sentiment CLSD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLSD Articles This Week▼53▲CLSD Articles Average Week Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sage Therapeutics News Today Jasper Therapeutics News Today Valneva News Today C4 Therapeutics News Today 4D Molecular Therapeutics News Today Immutep News Today COMPASS Pathways News Today AC Immune News Today Amylyx Pharmaceuticals News Today iTeos Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLSD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
